The Clinical Characteristics and Treatment Response of Patients with Low Grade Non-Hodgkin Lymphoma | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 11, Volume 74, Issue 4, January 2019, Page 789-796 PDF (477.26 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2019.24356 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ahmed Yosry El-Agamawi; Mohammed El-Sayed Abd-El-Fattah Mansy; Mohamed Omar Ahmed 
| ||||
| Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt | ||||
| Abstract | ||||
| Background: as the histopathologic diagnosis of Non-Hodgkin Lymphoma (NHL) has become more sophisticated with the use of immunologic and genetic techniques, the understanding and treatment of many of the previously described pathologic subtypes have changed. Aim of the Work: was to review the clinicopathologic characteristics of the NHL patients, to assess the treatment response to the different treatment modalities available at our center and to analyze the correlation between patient’s characteristics, treatment modality and the achieved response. Patients and Methods: the current work was a retrospective study reviewing the data of patients with pathologically confirmed diagnosis of low-grade NHL referred to Al Hussein university Hospital, Department of Clinical Oncology, Faculty of Medicine, Al-Azhar University during the period between January 2012 till December 2016. Results: more than half the study group (57.2%) had the age between 41 and 60 years. Only 14.2% of the study group was younger than 40 years and 28.6% were older than 60 years. There was no difference between patients with CLL and patients with Low grade NHL as regards the age distribution. NHL in this study was equal among both males and females in both above 40 and below 40 age groups, unlike what was mentioned before which stated that NHL is more common in males than in females. Conclusion: only 31 patients were evaluable for survival analysis with median follow up period of 15 months. Median disease-free survival (DFS) was 12 months (95% CI 0-72.9). | ||||
| Keywords | ||||
| Clinical Characteristics; Non-Hodgkin lymphoma | ||||
|
Statistics Article View: 131 PDF Download: 335 |
||||
